OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial
Claire Harrison, Ruben A. Mesa, Moshe Talpaz, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 10, pp. e729-e740
Closed Access | Times Cited: 6
Claire Harrison, Ruben A. Mesa, Moshe Talpaz, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 10, pp. e729-e740
Closed Access | Times Cited: 6
Showing 6 citing articles:
Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and “real-world” data
Adrian Duek, Ilona Leviatan, Osnat Jarchowsky Dolberg, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Adrian Duek, Ilona Leviatan, Osnat Jarchowsky Dolberg, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
SOHO State of the Art Updates and Next Questions | Challenging Scenarios in the Management of Myeloproliferative Neoplasms
Joseph Cannova, Shiv Shah, Anand Patel
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Joseph Cannova, Shiv Shah, Anand Patel
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Fedratinib for patients with myelofibrosis – Authors’ reply
Claire Harrison, Patrick A. Brown, Jean‐Jacques Kiladjian
The Lancet Haematology (2025) Vol. 12, Iss. 4, pp. e241-e242
Closed Access
Claire Harrison, Patrick A. Brown, Jean‐Jacques Kiladjian
The Lancet Haematology (2025) Vol. 12, Iss. 4, pp. e241-e242
Closed Access
Fedratinib for patients with myelofibrosis
Sophie Le Grand, Pierre Guy, Suzanne Tavitian, et al.
The Lancet Haematology (2025) Vol. 12, Iss. 4, pp. e240-e241
Closed Access
Sophie Le Grand, Pierre Guy, Suzanne Tavitian, et al.
The Lancet Haematology (2025) Vol. 12, Iss. 4, pp. e240-e241
Closed Access
Fedratinib for patients with myelofibrosis
Ruben Van Dijck, John‐John B. Schnog, Peter te Boekhorst
The Lancet Haematology (2025) Vol. 12, Iss. 4, pp. e240-e240
Closed Access
Ruben Van Dijck, John‐John B. Schnog, Peter te Boekhorst
The Lancet Haematology (2025) Vol. 12, Iss. 4, pp. e240-e240
Closed Access
What are the therapeutic options for previously treated myelofibrosis?
C. Petit, Hugues de Lavallade, Claire Harrison
Expert Review of Hematology (2024), pp. 1-12
Closed Access
C. Petit, Hugues de Lavallade, Claire Harrison
Expert Review of Hematology (2024), pp. 1-12
Closed Access
JAK Inhibitors for Myelofibrosis: Strengths and Limitations
Kyaw Htin Thaw, Claire Harrison, Priya Sriskandarajah
Current Hematologic Malignancy Reports (2024) Vol. 19, Iss. 6, pp. 264-275
Open Access
Kyaw Htin Thaw, Claire Harrison, Priya Sriskandarajah
Current Hematologic Malignancy Reports (2024) Vol. 19, Iss. 6, pp. 264-275
Open Access
Fedratinib as an alternative to splenectomy for refractory splenomegaly prior to transplant for myelofibrosis
James T. England, Taylor Nye, Verna Cheung, et al.
Bone Marrow Transplantation (2024)
Closed Access
James T. England, Taylor Nye, Verna Cheung, et al.
Bone Marrow Transplantation (2024)
Closed Access
When, which and how to switch: Navigating JAK inhibitors in myelofibrosis
Jennifer O’Sullivan, Imran Omerdeen, Bethan Psaila
British Journal of Haematology (2024)
Closed Access
Jennifer O’Sullivan, Imran Omerdeen, Bethan Psaila
British Journal of Haematology (2024)
Closed Access
